Actos Linked to Heart Attacks
Research has shown that Actos users have a higher risk of congestive heart failure and heart attacks than non-users. Takeda Pharmaceuticals ran many clinical trials which suggested that Actos users were at risk of serious heart problems. Despite the clinical trials of Actos suggesting heart problems, it was released to the market.
Edema is a possible side effect from Actos. Edema is the accumulation of fluids in the body. Heart failure can cause the body to be congested with fluids that can shut down major organs. Because Actos can cause edema, this seriously complicates existing heart conditions.
Actos Bladder Cancer Lawyer
Actos has been linked to bladder cancer. If you or a loved one has developed bladder cancer after taking or while taking Actos, you should contact a, Actos injury lawyer for help. We know you want justice for your bladder cancer that could be from your Actos use.
$9 Billion Jury Verdict Against Actos Manufacturers
In June 2011, the Food and Drug Administration found that people who took Actos for more than one year had an increased risk of bladder cancer. The FDA ordered Actos to carry stronger warnings on its drug label. After the FDA’s warning, many lawsuits were filed. In April 2014, Takeda Pharmaceutical Company and Eli Lilly, the manufactures of Actos, were ordered by a court to pay punitive damages of $9 billion for ignoring cancer risks.
Other Side Effects From Actos
Actos is thought to have caused more side effects than just bladder cancer, heart failure, and heart attacks. Actos is believed to also cause blood in urine, dental problems, increased thirst or hunger, liver disease, painful urination, shortness of breath, stomach pain, swelling, and rapid weight gain.
Different Products, Same Risk
The active ingredient in Actos (pioglitazone) is also sold in combination with metformin (Actoplus Met®, Actoplus Met XR®) and glimepiride (Duetact®). From January 2010 through October 2010, approximately 2.3 million patients filled prescriptions for a pioglitazone-containing product from outpatient retail pharmacies.
Compensation for Actos Bladder Cancer Injuries
Victims of Actos may be entitled to money for medical bills, pain and suffering, lost wages, and possibly even punitive damages. If you suspect your bladder cancer is from taking Actos, contact a drug injury lawyer soon. You may only have a limited amount of time to file an Actos injury lawsuit.
Actos® Bladder Problems
The U.S. Food and Drug Administration (FDA) warns that use of the diabetes medication Actos® (pioglitazone) for more than one year has been associated with a 40 percent increase in risk for bladder cancer. The FDA urges patients who have taken Actos to contact a medical professional immediately if they experience any of the following symptoms:
- Blood or red color in urine
- Urgent need to urinate or pain while urinating
- Pain in back or lower abdomen
Information about the risk of bladder cancer associated with Actos has been added to the “warnings and precautions”section of the label for pioglitazone-containing medicines as well as the patient medication guide.
In April 2014, a jury found that the manufacturers of Actos, Takeda Pharmaceutical Company Limited and Eli Lilly & Company, hid the cancer risks of the drug. The two companies were ordered to pay a combined $9 Billion in punitive damages—the seventh-largest jury award in U.S. history.
Get the Help You Deserve
If you or someone you love has taken a diabetes medication containing pioglitazone and was diagnosed with bladder cancer, you may be entitled to compensation. Contact us immediately for a free and confidential case evaluation, and get the help you deserve.
Never stop taking any medication without first consulting your doctor. Actos®, Actoplus Met®, Actoplus Met XR®, and Duetact® are registered trademarks of Takeda Pharmaceutical Company Limited and are used here only for the purpose of identifying the products in question. This law firm is not associated with, sponsored by, or affiliated with the U.S. Food and Drug Administration, Takeda Pharmaceutical Company Limited, Eli Lilly & Company, or Bloomberg.